成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Toggle Nav
Close
  • Menu
  • Setting

Deferoxamine mesylate

Catalog No.
B6068
iron-chelating agent
Grouped product items
SizePriceStock Qty
100mg
$55.00
In stock
500mg
$99.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Deferoxamine mesylate is a specific iron-chelating agent [1][2][3]

Deferoxamine mesylate can be used for treating acute iron intoxication. Deferoxamine complexed with iron to form ferrioxamine and then prevented the iron from entering into further chemical reactions. The formed chelate is readily soluble in water and passes easily through the kidney [1].

In Fisher rats transplanted with the 13762NF mammary adenocarcinoma, deferoxamine mesylate reduced rat tumor growth. While deferoxamine mesylate?injections plus a low iron diet caused the greatest inhibitory effect on tumor growth. Deferoxamine mesylate may be a useful chemotherapeutic agent in the treatment of breast cancer [2]. In Sprague-Dawley rats, injected with deferoxamine mesylate (75-90 mg; 300 mg/kg) via the celiac artery before surgery. Deferoxamine mesylate signi?cantly lowered the serum levels of amylase, lipase, and malondialdehyde (MDA) after orthotopic liver autotransplantation. Deferoxamine mesylate also protected pancreatic tissue through up-regulated expression of HIF-1 protein and inhibition of oxidative toxic reactions [3].

References:
Deferoxamine mesylate (Desferal mesylate).  A specific iron-chelating agent for treating acute iron intoxication. Clin Pharmacol Ther. 1969 Jul-Aug;10(4):595-6.
Wang F, Elliott RL, Head JF.  Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res. 1999 Jan-Feb;19(1A):445-50.
Li Y, Zhang PJ, Jin C, et al.  Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplant Proc. 2011 Jun;43(5):1450-5.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt656.79
Cas No.138-14-7
FormulaC26H52N6O11S
Solubility≥65.7 mg/mL in H2O; insoluble in EtOH; ≥29.8 mg/mL in DMSO
Chemical Name(Z)-4-((5-aminopentyl)(hydroxy)amino)-N-(5-((Z)-N,4-dihydroxy-4-((5-(N-hydroxyacetamido)pentyl)imino)butanamido)pentyl)-4-oxobutanimidic acid compound with methanesulfonic acid (1:1)
SDFDownload SDF
Canonical SMILESCC(N(O)CCCCC/N=C(O)/CCC(N(O)CCCCC/N=C(O)/CCC(N(O)CCCCCN)=O)=O)=O.CS(O)(=O)=O
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]

Cell lines

Adipose derived mesenchymal stem cells (AdMSCs)

Reaction Conditions

30, 60 or 120?μM deferoxamine mesylate for 12 h inubation

Applications

Cells exposed to 30 or 60 μM of deferoxamine mesylate showed significantly lower expression of hypoxia-inducible factor-1α (HIF-1α) when compared with cells cultured under 1% O2, but cell treated with 120 μM deferoxamine mesylate was able to mimic cells under hypoxic conditions. Deferoxamine mesylate could promote wound healing in AdMSCs through HIF-1α stabilization.

Animal experiment:[2]

Animal models

Sprague-Dawley rats, 0.25 ~ 0.30 kg

Dosage form

75 ~ 90 mg; 300 mg/kg

Injected via the celiac artery at 24 and 48 hours before orthotopic liver autotransplantation

Applications

Deferoxamine mesylate significantly lowered the serum levels of amylase, lipase, and malondialdehyde after orthotopic liver autotransplantation. Deferoxamine mesylate also protected pancreatic tissue through up-regulated expression of HIF-1α protein and inhibition of oxidative toxic reactions.

Note

The technical data provided above is for reference only.

References:

1. Wahl EA, Schenck TL, Machens HG, et al. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Scientific Reports, 2016, 6: 36879.

2. Li Y, Zhang PJ, Jin C, et al. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplantation Proceedings, 2011, 43(5): 1450-1455.

Quality Control

Chemical structure

Deferoxamine mesylate

Related Biological Data

Deferoxamine mesylate

Related Biological Data

Deferoxamine mesylate

Related Biological Data

Deferoxamine mesylate